Publication
Article
BioPharm International
Due Diligence Assessment of CMC Activities
Author(s):
For planned acquisitions or licensing, careful analysis of CMC factors ensures no problem areas are overlooked.
Developing comprehensive chemistry, manufacturing, and controls programs are crucial to the success of a drug product. For planned acquisitions or licensing, a careful analysis of these critical factors is vital to ensure no problem areas are overlooked. Strategies for carrying out an effective due diligence exercise are described
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
Article Details
BioPharm International
eBook: Regulatory Sourcebook
October 2020
Pages: 42–44
Citation
When referring to this article, please cite it as W. Lambert, “Due Diligence Assessment of CMC Activities," BioPharm International Regulatory Sourcebook eBook (October 2020).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
